Sign in
Taking people in United StatesNo phase

Tracks health and artery cholesterol in people with a rare inherited high-cholesterol disorder

Records health and blood over time in people with homozygous familial hypercholesterolemia.

Key facts

Who runs it
The Rogosin Institute
Where
New York, United StatesSee the site
Trial code
Registry title
The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository
Status
Recruiting
People taking part
60 people, planned
Started
Jun 2010
Expected to end
May 2030
Type of study
Observational
Record updated
6 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and adults of any age who have homozygous familial hypercholesterolemia (hoFH), a rare inherited condition with very high cholesterol from birth.

Age
Any age.
Sex
Men and women can both join.
Disease stage
Homozygous familial hypercholesterolemia (hoFH), shown by clinical signs or by gene testing. Untreated fasting LDL cholesterol above 500 mg/dL (12.9 mmol/L) and triglycerides below 200 mg/dL (2.3 mmol/L), on a cholesterol-lowering diet for at least 8 weeks, with other causes ruled out.
Earlier treatment
Untreated LDL cholesterol level must be documented. Having been on a cholesterol-lowering diet for at least 8 weeks.
Biomarker or test result
The trial is looking for one of these: a double mutation of the LDL receptor or apoB gene; LDL above 160 mg/dL (4.1 mmol/L) in both biological parents; coronary artery disease in a parent or grandparent before age 55 (men) or 65 (women); or skin or tendon fatty deposits (xanthomas) before age 10 or coronary artery disease before age 20.

Main reasons for not taking part

  • The patient (or a parent, if under 18) cannot sign informed consent.

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Patients of any age and sex who meet clinical or genetic criteria for hoFH as follows:
  • Documented, untreated fasting LDL cholesterol level of > 500 mg/dL and triglycerides < 200 mg/dL on a cholesterol-lowering diet for at least 8 weeks with secondary causes excluded, AND:; DNA confirmation of a double mutation of the LDL receptor or apoB gene OR; LDL > 160 mg/dL in both biological parents not associated with a disorder know to elevate LDL OR; Coronary artery disease in one or both parents or grandparents < 55 years for males, < 65 for females OR; Tendinous/cutaneous xanthomas < age 10 or coronary artery disease < age 20

Who cannot take part

  • Inability of patient, or, if less than 18, a parent, to sign informed consent

Where in United States

  • Weill Cornell Medical CollegeNew York, United StatesContact: Lisa C. Hudgins, M.D.Taking people

About the trial

What the trial wants to find out

This repository will establish for the first time a system to carefully assess and monitor over time the general health and the amount of cholesterol in the arteries of U.S. children and adults with homozygous familial hypercholesterolemia (hoFH). Patients with this very rare disorder have very high blood levels of cholesterol from birth due to the inheritance of an abnormal gene from each parent. As a result, if untreated, heart attacks and sudden death occur in childhood. Treatments such as LDL-apheresis and liver transplant will lower the cholesterol level, but the best treatment and the best way to monitor the effect of the treatment on the arteries are unknown. The collection of clinical data and blood for analysis of known and yet-to-be discovered markers and predictors of arterial disease will yield new information about the natural history of the disorder and response to treatment. The repository will greatly aid the development of specific protocols that seek to learn more about this disease and new therapies.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository
Plain-language title
Tracks health and artery cholesterol in people with a rare inherited high-cholesterol disorderGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
6 April 2026